An observational study has found that high and increasing blood pressure (BP) from early adulthood into midlife seems to be associated with increased white matter hyperintensity volume (WMHV) and smaller brain volumes at 69 to 71 years of age.
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.
In patients with type 2 diabetes mellitus (T2DM) and stable coronary artery disease (CAD) without prior MI or stroke, ticagrelor plus low-dose aspirin significantly reduces ischaemic cardiovascular (CV) events vs aspirin alone, at the expense of increased major bleeding, with a favourable net clinical benefit observed in those with a history of percutaneous coronary intervention (PCI).
Use of ezetimibe to manage elevated low-density lipoprotein cholesterol (LDL-C) levels in individuals aged ≥75 years proves beneficial in the primary prevention of coronary artery disease (CAD) events, reducing the risk of a composite of sudden cardiac death, myocardial infarction, coronary revascularization or stroke, according to data from the open-label EWTOPIA* 75 trial.
Spending excessive time on the smartphone daily, ie, 5 hours or more per day, may promote unhealthy eating habits and a sedentary lifestyle, thus leading to obesity among young people, according to a study presented at the recent American College of Cardiology (ACC) Latin America Conference 2019 held in Cartagena, Colombia.
Long-term treatment with perindopril, an angiotensin-converting enzyme (ACE) inhibitor, results in decreased soluble endoglin (sEng) plasma levels in hypertensive patients with endothelial dysfunction, a new study shows.
Use of implantable cardioverter-defibrillator (ICD) in the prevention of sudden cardiac death or all-cause mortality in a well-screened and well-treated population undergoing dialysis does not appear to be effective, with the incidence of said outcomes remaining high, according to data from the ICD2* trial.
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
A comprehensive model of care delivered by nonphysician health workers (NPHWs), involving primary care physicians and families that was informed by local context, substantially improved blood pressure (BP) control and cardiovascular disease (CVD) risk, according to results of the HOPE 4 trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.